I have been asked about different measures of dementia and their impact on the trials. There are two basic aspects of these measures and dementia. There is the innate to human cognition nature of deterioration resulting in greater or lesser progress to an observer.There is the sensitivity of type and mix of measures build into … Continue reading Measures of Dementia in Alzheimer’s and Their Distortion of Trial Results $AVXL $LLY Blarcamesine Donanemab

In the list of the banes of our brains neuroinflammation has its lion's share. Indeed, only the Amyloid plaque can compete with it on cenceptual level in medicine nowadays. This ancient way of defending multicellular organisms from harm and infection can easly turn into the damage itself. Similarly, the probable etiology of Alzheimer's can be … Continue reading Cortexyme and The Brave New Ideas in Alzheimer’s Drugs. $CRTX $SAVA $ATHA $AVXL

I have a sleepless night so...... The 3xTg (Tg for transgenic) murine model of Alzheimer's disease uses the same gene, PSEN1 (actually, a trasngenic version of the mutation prevalent in familial AD) and two others are connected to amyloid plaque and Tau deposits. The same mutation was used in the experiments described in paper linked … Continue reading Cassava Sciences Drug Simufilam in The Pecking Order of New Breed of Alzheimer’s Drugs. $SAVA $AVXL $BIIB $LLY

Please, read the latest news from $AVXL (3-16-2021), first. There is a link here: https://www.anavex.com/anavex-life-sciences-reports-anavex2-73-blarcamesine-featured-as-a-disease-modifying-small-molecule-in-phase-3-clinical-trials-in-a-new-publication-in-medical-journal-titled-future-av/ My take on this is that we are being given early insight into the result of the phase2b/3 (Alzheimer's). The company has never kept the same group of patients to present the data or rather it kept changing many metrics … Continue reading Can Blarcamesine Rescue Those Above MMSE 20 With Alzheimer’s? $AVXL Blarcamesine

I have listen to the webinar from Elli Lilly $LLY on 15th of March, 2021 about the phase 2 Donanemab results. The biotech business is fraught with failure, and spinning the results so that investors won't lose hope and leave. In just couple of years, we have witnessed triple failures of monoclonal antybodies aimed at … Continue reading Eli Lilly’s Donanemab And The Lack of Little Ideas Among The Big Pharma Giants $LLY Donanemab $AVXL

The advancements in the genetics and the growing body of knowledge of embryonic development have altered the search for the cause of Alzheimer’s disease, and many neurodegenerative diseases. The new paradigm fixes the primary cause to lie within the cellular gene transcription mechanism of the neurons leading to their degeneration into a kind of dysfunctional … Continue reading Athira Pharma Revisited. Future Cure for Alzheimer’s or A Dud. $ATHA $AVXL ATH-1017 Blarcamesine

Many neurodegenerative and neurodevelopmental diseases might have a similar mechanism. These might be Parkinson's, Rett syndrome, Fragile X syndrome, and Autism. The Amyloid and Tau plaque theory has been superseded but will die slowly. ($SAVA $BIIB) New types of drugs will emerge to address this paradigm change. AVXL already has drugs to address the new … Continue reading Novel Etiology of Alzheimer’s linked to neuronal loss of function due to changes in cellular transcription mechanism and DNA Chromatin Complex. $AVXL $SAVA $ATHA $BIIB